TFPI-2 is downregulated in many aggressive tumors, such as gliomas [43], non-small cell lung cancer (NSCLC) [44, 45], breast cancer (BC) [46], melanoma [47], colorectal cancer (CRC) [48], pancreatic cancer (PC) [49], hepatocellular carcinoma (HCC) [50], gastric stromal tumor, cervical cancer [51], and prostate cancer [52]. Here, TFPI2 is linked to central nervous system cancer.